ATE263162T1 - Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren - Google Patents

Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren

Info

Publication number
ATE263162T1
ATE263162T1 AT00927523T AT00927523T ATE263162T1 AT E263162 T1 ATE263162 T1 AT E263162T1 AT 00927523 T AT00927523 T AT 00927523T AT 00927523 T AT00927523 T AT 00927523T AT E263162 T1 ATE263162 T1 AT E263162T1
Authority
AT
Austria
Prior art keywords
linkage
heteroaryldiyl
compounds
aryldiyl
heterocycloalkylene
Prior art date
Application number
AT00927523T
Other languages
English (en)
Inventor
Paul Robert Aventis P Eastwood
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910417.6A external-priority patent/GB9910417D0/en
Priority claimed from GBGB9910405.1A external-priority patent/GB9910405D0/en
Priority claimed from GBGB9910396.2A external-priority patent/GB9910396D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ATE263162T1 publication Critical patent/ATE263162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00927523T 1999-05-05 2000-05-05 Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren ATE263162T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9910417.6A GB9910417D0 (en) 1999-05-05 1999-05-05 Chemical compounds
GBGB9910405.1A GB9910405D0 (en) 1999-05-05 1999-05-05 Chemical compounds
GBGB9910396.2A GB9910396D0 (en) 1999-05-05 1999-05-05 Chemical compounds
US15286199P 1999-09-08 1999-09-08
US15286099P 1999-09-08 1999-09-08
US15285599P 1999-09-08 1999-09-08
PCT/GB2000/001734 WO2000068223A1 (en) 1999-05-05 2000-05-05 Ureas and their use as cell adhesion modulators

Publications (1)

Publication Number Publication Date
ATE263162T1 true ATE263162T1 (de) 2004-04-15

Family

ID=27547334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927523T ATE263162T1 (de) 1999-05-05 2000-05-05 Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren

Country Status (8)

Country Link
US (1) US6620832B2 (de)
EP (1) EP1177186B1 (de)
AT (1) ATE263162T1 (de)
AU (1) AU4591800A (de)
CA (1) CA2370805C (de)
DE (1) DE60009480T2 (de)
ES (1) ES2218156T3 (de)
WO (1) WO2000068223A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1158985B1 (de) 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
JP4212358B2 (ja) 2000-12-28 2009-01-21 第一三共株式会社 Ｖｌａ−４阻害薬
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
EP1663978B1 (de) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP1684762A4 (de) * 2003-11-13 2009-06-17 Ambit Biosciences Corp Harnstoff-derivate als kinase-modulatoren
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (de) 2005-09-14 2008-05-28 Amgen, Inc Konformationseingeschränkte 3- (4-hydroxy-phenyl) substitutierte propansäuren zur behandlung von stoffwechselstörungen
EP2064193A1 (de) * 2006-09-07 2009-06-03 Amgen, Inc Heterozyklische gpr40-modulatoren
CA2662242C (en) * 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2008241490B2 (en) * 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2015145371A1 (en) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212320A (en) * 1990-05-21 1993-05-18 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives and their use for testosterone 5-alpha-reductase-mediated diseases
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1005445B1 (de) * 1997-08-22 2004-05-26 F. Hoffmann-La Roche Ag N-alkanoylphenylalaninderivate
WO1999020272A1 (en) * 1997-10-21 1999-04-29 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
EA200000868A1 (ru) * 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипаз
US6608084B1 (en) * 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
ES2297943T3 (es) * 1998-12-23 2008-05-01 Aventis Pharma Limited Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
SE514227C2 (sv) 1999-01-20 2001-01-22 Tore Kaellander Anordning inrättad att kyla ett maskinaggregat som är inrättat att vara associerat med en motor

Also Published As

Publication number Publication date
US6620832B2 (en) 2003-09-16
US20020082255A1 (en) 2002-06-27
EP1177186B1 (de) 2004-03-31
EP1177186A1 (de) 2002-02-06
AU4591800A (en) 2000-11-21
DE60009480D1 (de) 2004-05-06
DE60009480T2 (de) 2005-09-01
WO2000068223A1 (en) 2000-11-16
ES2218156T3 (es) 2004-11-16
WO2000068223A8 (en) 2001-03-01
CA2370805A1 (en) 2000-11-16
CA2370805C (en) 2012-07-03

Similar Documents

Publication Publication Date Title
ATE263162T1 (de) Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
BG106083A (en) Substituted bicyclic heteroaryl compounds as integrin antagonists
NO20020725D0 (no) Celleadhesjonsinhibitorer
US5519005A (en) Method of inhibition of cellular and molecular level biological interactions utilizing non-peptidic surrogates of the Arg-Gly-Asp sequence
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
MXPA01001995A (es) Aza-biciclos que modulan la inhibicion de adhesion celular.
PE106499A1 (es) Antagonistas del receptor ccr-3
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
TR199901674T2 (de)
DK148392D0 (da) Heterocykliske forbindelser
HUP0303037A2 (hu) Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
TR200102038T2 (tr) Amid bileşenler
MA33107B1 (fr) Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
ATE281433T1 (de) Substituierte pyrrolidine als inhibitoren der zelladhäsion
AR015964A1 (es) Compuestos de isoquinolina, su uso, procedimiento para tratar una afeccion, procedimiento de preparacion del compuesto, composicion farmaceutica que locontiene y compuesto util en dicho procedimiento
DE59707524D1 (de) 1,3-bis-(n-lactamyl)propane und deren pharmazeutische und kosmetische verwendung
CO5140091A1 (es) Derivados de piperidina y piperazina, su preparacion, su uso como productos farmaceuticos y composiciones farmaceuticas que los contienen
DE69333944D1 (de) Neuer pyridon-derivat der eine affinität für den angiotensin-ii-rezeptor hat
AP2000001924A0 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines.
HUP9702149A2 (hu) Tachykinin receptor antagonista heterociklikus piperazinonszármazékok, intermedierjeik, előállításuk és alkalmazásuk, valamint a vegyületeket tartalmazó gyógyászati készítmények
DK0827500T3 (da) (2-morpholinylmethyl)benzamid-derivater
YU71501A (sh) Supstituisana biciklična heteroaril jedinjenja kao antagonisti integrina
EA200001077A3 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties